Renate P.
- Country
- Austria
- Department
- Department of Urology
Research Overview
- Phase 3 Randomized Trial of Intravesical Erdafitinib Delivery System vs. Single-Agent Chemotherapy in FGFR+ Intermediate-Risk Non-Muscle Invasive Bladder Cancer
- A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed During or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment. TROPION-Urothelial03 (TU03).
- IZABRIGHT-BLADDER01: A Randomized, Open-label, Phase 2/3 trial of Izalontamab Brengitecan versus platinum-based chemotherapy for metastatic urothelial cancer in participants with disease progression on or after an immunotherapy-based treatment
Data & Insights
Has run more than one trial at 46 of 183 partner sites.
Specializations
Urologic Oncology
This investigator specializes in the study and treatment of non-muscle invasive bladder cancer, with particular emphasis on cases involving FGFR gene alterations. Their research focuses on innovative therapeutic approaches for bladder cancer management.
- Bladder Cancer Treatment
- Targeted Therapy Development
- Intravesical Therapy
The investigator's work encompasses evaluating treatment outcomes and exploring novel therapeutic strategies for intermediate-risk bladder cancer patients.
Molecular Oncology
The investigator's expertise extends to the field of molecular targeted therapies, specifically focusing on FGFR-positive cancers. Their research involves studying genetic alterations and their role in cancer development.
- Genetic Profiling
- Biomarker Analysis
- Personalized Medicine
Their work contributes to advancing personalized treatment approaches based on specific genetic markers in bladder cancer.
Clinical Outcomes
The investigator focuses on evaluating disease-free survival and treatment effectiveness in bladder cancer patients. Their research emphasizes comparing different therapeutic approaches to optimize patient outcomes.
- Treatment Comparison Studies
- Survival Analysis
- Risk Assessment
They are involved in assessing therapeutic interventions for intermediate-risk bladder cancer patients through comparative clinical research.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.